Information Provided By:
Fly News Breaks for August 6, 2018
PCRX
Aug 6, 2018 | 06:39 EDT
As previously reported, BofA/Merrill downgraded Pacira to Neutral from Buy and raised its price target to $46 from $39 following the Q2 beat. Analyst Tazeen Ahmad said shares now reflect 20%+ annual growth and are fully valued.
News For PCRX From the Last 2 Days
There are no results for your query PCRX